ProCE Banner Activity

Our Thoughts on Managing Patients With ROS1-Rearranged Advanced NSCLC: Answers to Frequently Asked Questions

Clinical Thought

Read this commentary with our answers to frequently asked questions on the optimal clinical management of patients with ROS1-rearranged advanced NSCLC.

Released: September 10, 2024

Expiration: September 09, 2025

Share

Faculty

Jessica J Lin

Jessica J Lin, MD

Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice Shaw

Alice Shaw, MD, PhD

Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Bristol-Myers Squibb.

Bristol Myers Squibb

Faculty Disclosure

Primary Author

Jessica J Lin, MD

Attending Physician
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Jessica J. Lin, MD: consultant/advisor/speaker: AnHeart Therapeutics, AstraZeneca, Bayer, Blueprint Medicines, Bristol Myers Squibb, C4 Therapeutics, Claim Therapeutics, Daiichi Sankyo, Elevation Oncology, Ellipses, Genentech, Hyku BioSciences, Merus, Mirtati Therapeutics, Novartis, Nuvalent, Pfizer, Regeneron, Takeda, Turing Point Therapeutics, Yuhan; researcher (paid to institution): Bayer, Elevation Oncology, Hengrui Therapeutics, Linnaeus Therapeutics, Neon Therapeutics, Novartis, Nuvalent, Pfizer, Roche, Relay Therapeutics, Turning Point Therapeutics; other (travel support): Merus, Pfizer.

Alice Shaw, MD, PhD

Chief, Strategic Partnerships
Attending Physician, Thoracic Oncology
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Alice Shaw, MD, PhD: employee (relationship has ended): Novartis.